Our unique CDMO services

Small molecular manufacturing

Large molecular manufacturing

High potency & ADC services

Development & Scale up

AAV Vector manufacturing

Oligonucleotide & Peptide synthesis

Product quality services

AJINOMOTO BIO•PHARMA SERVICES

THE POWER TO MAKE

Oligonucleotides / Peptides

Oligonucleotide Manufacturing (by solid phase synthesis)

Offer variety of types oligonucleotides.

- ASO
- CpG ODN
- Aptamer
- Decoy
- Probes
- siRNA
- sgRNA, long chain RNA
- miRNA mimic / inhibitor
- Conjugation with peptide / fluorescence
- Enzymatic conjugation

Research Use | In vitro diagnostics materials | API for clinical use

You can choose liquid synthesis manufacturing, AJIPHASE® .

Innovative Liquid Phase Synthesis for Oligonucleotide, Peptide, PMO and PPMO

AJIPHASE®

AJIPHASE® is a hybrid of solid and solution phase syntheses that uses an anchor to make the molecules very soluble in non-polar solvents, providing a homogenous mixture.

- Mass production with High quality
- Seamless scale up from lab to commercial
- High reproductivity



Green Chemistry | FDA approval

Proteins

Secretion Production of Peptides/Proteins by Endotoxin-free Microorganism『CORYNEX®』

Value of CORYNEX®

- ◆ Endotoxin-free, high-purity protein secretion platform
- ◻ **Endotoxin-free** *C. glutamicum* as host cell
- ◻ Purification process can be simplified
- ◆ Applicable for expression of various proteins
- ◻ Especially highly suitable for **VHH**, **antibody mimetics** and **long peptides**

E.coil (traditional system)



CORYNEX® (our system)

Long Chain RNA Synthesis Technology

High-Quality RNA Production Achieved through the Integration of Multiple Domain Technologies

The integration of traditional RNA synthesis technology with CORYNEX® technology enables the production of high-quality and highly efficient oligonucleotides.

- ◻ Single-Stranded RNA Production (100-600 Bases)
- ◻ Removal of N±1 mer during the ligation process
- ◻ High ligation efficiency using proprietary enzymes
- ◻ Double-Stranded RNA Production (Approx. 21 Bases)
- ◻ Partial Chemical Modifications (e.g., 2’ -F, 2’ -OMe modifications, insertion of special bases)

Summary of Production



Innovative Long-Chain RNA Synthesis

Flexible Chemical Modification

WO2024048684 Method For Producing Nucleic Acid Molecule
WO2020171092 Method For Producing Modified Oligonucleotide Including Complementary Sequence

ADC Technology

Site-Specific Conjugation and Linker Technologies

- No genetic engineering and no enzyme required
- ADCs with higher efficacy and lower toxicity achieved
- Applicable for any IgG molecule and a variety of payloads

AJICAP®

AJICAP Technology: Novel conjugation and linker technologies

位置選択的結合

- ✓ Simple operation
- ✓ No genetic engineering
- ✓ Precise DAR control

AJICAP Conjugation + AJICAP Novel linker

***in vivo*特性の増強**

- ✓ Increasing plasma stability
- ✓ Increasing hydrophilicity
- ✓ Resistant to neutrophil protease



Isotype	mAb
hIgG1	▪ Monoclonal Ab ▪ Chimeric mAb ▪ Engineered mAb ▪ Deglycosylated mAb ▪ BisAb ▪ Fc protein ▪ Polyclonal antibodies
hIgG2	
hIgG4	
Mouse, Rat antibody	

Conjugation site
Lys248
Lys288
Lys248 & 288

Attachment
Thiol
Azide
DBCO

Payload / Toxins
Small molecule MMAE, Exatecan, PBD etc.
Protein Peptide
Oligonucleotide
Cargo molecule LNP, Liposome etc.
Cell

ADCs generated by AJICAP® site-specific conjugation and stable & hydrophilic linker has higher efficacy and lower toxicity.



AAV vectors and plasmids

AAV vectors and plasmids through the FUEL™ Platform

The FUEL™ Platform, utilizing proprietary plasmids and cell lines, achieves high efficiency and yield. We cater to a wide range of needs, from research to commercial use.

The Unique Technology of the FUEL™ Platform

- pEMBR 2.0™ Ad Helper
- Modified Rep/Caps
- Ignition Cells™



High Stability and Productivity

Over 260 Production Lots

200,000 L total production capacity and scalability





Small Molecular Manufacturing

Providing high quality APIs and intermediates, from lab scale through pilot to commercial production.

Multipurpose production facilities

Robust development

Expertise	High potency APIs
	Cryogenic & high pressure reactions
	High energy chemistries
	Biocatalysis
	Continuous flow technology
	Controlled substances (EU)
	Complex chemistries

Our Global Operation



Belgium
- Small molecule manufacturing
- Continuous flow
- Highly Potent APIs

Japan
- Oligonucleotide & Peptide synthesis
- AJIPHASE® Technology
- CORYNEX® & TALAMAX®
- AJICAP®
- Central Aji Co. R&D for new technologies (Protein, ADC)

United States
- AAV vectors and plasmids manufacturing

India
- Small molecule manufacturing

Ajinomoto Bio-Pharma Services

Our original technology

Contact

Ajinomoto Bio-Pharma Services
GeneDesign, Inc.

〒567-0085 7-7-29 Saitoasagi Ibaragi, Osaka
E-mail:gdi_info@jp.ajibio-pharma.com

Notice;
The specification and prices are subject to change without notice.

As Nov 2025